Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All HCQ studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19hcq.org COVID-19 treatment researchHCQHCQ (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   
0 0.5 1 1.5 2+ Hospitalization -50% Improvement Relative Risk Case -43% Case (b) 8% HCQ for COVID-19  de la Iglesia et al.  Prophylaxis Is pre-exposure prophylaxis with HCQ beneficial for COVID-19? Retrospective 1,375 patients in Spain More cases with HCQ (not stat. sig., p=0.15) c19hcq.org de la Iglesia et al., medRxiv, September 2020 Favors HCQ Favors control

Hydroxicloroquine for pre-exposure prophyylaxis for SARS-CoV-2

de la Iglesia et al., medRxiv, doi:10.1101/2020.08.31.20185314
Sep 2020  
  Post
  Facebook
Share
  Source   PDF   All   Meta
HCQ for COVID-19
1st treatment shown to reduce risk in March 2020
 
*, now known with p < 0.00000000001 from 421 studies, recognized in 42 countries.
No treatment is 100% effective. Protocols combine complementary and synergistic treatments. * >10% efficacy in meta analysis with ≥3 clinical studies.
3,800+ studies for 60+ treatments. c19hcq.org
Analysis of autoimmune disease patients on HCQ, compared to a control group from the general population (matched on age and sex, but not adjusted for autoimmune disease), showing non-significant differences between groups.
Other research shows that the risk of COVID-19 for systemic autoimmune disease patients is much higher overall, Ferri et al. show OR 4.42, p<0.001 Ferri, which is the observed real-world risk, taking into account factors such as these patients potentially being more careful to avoid exposure.
If we adjust for the different baseline risk, the mortality result becomes RR 0.35, p=0.23, suggesting a substantial benefit for HCQ treatment (as shown in other studies).
This study is excluded in the after exclusion results of meta analysis: not fully adjusting for the different baseline risk of systemic autoimmune patients.
risk of hospitalization, 50.0% higher, RR 1.50, p = 1.00, treatment 3 of 687 (0.4%), control 2 of 688 (0.3%).
risk of case, 42.6% higher, RR 1.43, p = 0.15, treatment 42 of 648 (6.5%), control 30 of 660 (4.5%), suspected COVID-19.
risk of case, 7.8% lower, RR 0.92, p = 0.84, treatment 12 of 678 (1.8%), control 13 of 677 (1.9%), NNT 665, confirmed COVID-19.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
de la Iglesia et al., 2 Sep 2020, retrospective, database analysis, Spain, preprint, 17 authors.
This PaperHCQAll
Hydroxicloroquine for Pre-Exposure Prophylaxis for SARS-COV-2
Jaime López De La Iglesia, Naiara Cubelos Fernández, Roi Naveiro Flores, Marina Montoro Gómez, Francisco Javier González De Haro, María Ajenjo González, Estefanía Tobal Vicente, María Lamuedra Gil De Gómez, María Teresa Nuevo Guisado, Isabel Torio Gómez, Ana Peñalver Andrada, Nuria Martínez Cao, Paula González Figaredo, Carlos Robles García, Lidia Anastasia Alvarado Machón, Ángeles Lafont Alcalde, José Cesáreo Naveiro Rilo
doi:10.1101/2020.08.31.20185314
SARS-CoV-2 infection has a high transmission level. At the present time there is not a specific treatment approved but it is known that, in vitro, chloroquine and hydroxychloroquine can inhibit the coronavirus. Objective: verifying if patients with autoimmune diseases that are on treatment with HCQ have less incidence and severity on COVID-19. Material and methods: this is a retrospective cohort study. The exposed cohort was formed by individuals with autoimmune diseases with HCQ treatment. The control cohort was randomly selected using the Health Card database. To deal with confounding variables and evaluate the effect of HCQ on the incidence and severity of SARS-CoV-2 infection, propensity score matching was used. Risk difference and paired percentage difference between exposed and non-exposed groups was estimated. Results: 919 individuals formed the exposed cohort and 1351 the control cohort. After matching, there were 690 patients on each group. During the time of the study, in the exposed group there were 42 (6.1%) individuals with suspected COVID-19, 12(1.7%) with confirmed COVID-19 and 3(0.4%) were hospitalized. In the control group there were 30(4.3%) individuals with suspected COVID-19, 13(1.9%) with confirmed COVID-19 and 2(0.3%) were hospitalized. The risk difference between each cohort was: 0.017(-0.05-0.04) for suspected COVID-19; -0.014(-0.015-0.012) for confirmed COVID-19 and 0.001(-0.007-0.007) for hospitalized patients. There were not significant differences. Conclusion: there is no difference neither on the incidence nor on the severity of COVID-19 between patients with autoimmune diseases with HCQ treatment and patients that do not take HCQ.
References
Ajenjo, None
Al-Kofaji, Jabobson, Boulware, Matas, Kandaswamy et al., Finding the Dos for Hydroxychloroquine Prophylaxis for COVID-19: The Desperate Search for Effectiveness, Clinical Pharmacology & Therapeutics, doi:10.1002/cpt.1874
Anastasia, Machón, None
Becker, Ichino, Estimation of average treatment effects based on propensity scores, The Stata journal
Biot, Daher, Chavain, Design and synthesis of hydroxyferroquine derivatives with antimalarial and antiviral activities, J Med Chem, doi:10.1021/jm0601856
Brady, Remarks by President Trump, Vice President Pence, and Members of the Coronavirus Task Force in Press Briefing
Buuren, Groothuis-Oudshoorn, Mice: Multivariate imputation by chained equations in R, Journal of statistical software
Buuren, Groothuis-Oudshoorn, Mice: Multivariate imputation by chained equations in R, Journal of statistical software
Cavalcanti, Zampieri, Regis, Hydroxychloroquine with or without Azithromycin in Mild-to-Moderate Covid-19, NEJM, doi:10.1056/NEJMoa2019014
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, doi:10.1101/2020.03.22.20040758
Chen, Hu, Zhang, Jiang, Han et al., Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial, Epidemiology, doi:10.1101/2020.03.22.20040758
Cubelos, None
Cummings, Baldwin, Abrams, Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study
Emmi, Bettiol, Mattioli, SARS-CoV-2 infection among patients with systemic autoimmune diseases, Autoimmun Rev, doi:10.1016/j.autrev.2020.102575
Francisco, Haro, None
Gautret, Lagier, Parola, Hoang, Meddeb et al., Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105949
Gianfrancesco, Hyrich, Al-Adelys, Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID 19 Global Rheumatology Alliance physician-reported registry
González, None
Joob, Wiwanitkit, SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217506
Konig, Kim, Scheetz, Graef, Liew et al., Baseline use of hydroxychloroquine in systemic lupus erythematosus does not preclude SARS-CoV-2 infection and severe COVID-19, Annals of the Rheumatic Diseases, doi:10.1136/annrheumdis-2020-217690
Lamuedra, De, None
Lee, Son, Peck, Can post-exposure prophylaxis for COVID-19 be considered as an outbreak response strategy in long-term care hospitals?, Int J Antimicrob Agents, doi:10.1016/j.ijantimicag.2020.105988
López, de la Iglesia 1
Mahévas, Tran, Roumier, Chabrol, Paule et al., Clinical efficacy of hydroxychloroquine in patients with COVID-19 pneumonia who require oxygen: observational comparative study using routine care data, BMJ, doi:10.1136/bmj.m1844
Martínez, None
Mathian, Mahevas, Rohmer, Roumier, Cohen-Aubart et al., Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-217566
Mehra, Desai, Td, Patel, Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19 (published on line, N Engl J Med
Million, Lagier, Gautret, Colson, Fournier et al., Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France, Travel Med Infect Dis, doi:10.1016/j.tmaid.2020.101
Montoro, None
Pablos, Abasolo-Alcázar, Álvaro-Gracia, Blanco, Prevalence of hospital PCR confirmed COVID-19 cases in patients with chronic inflammatory and autoimmune rheumatic diseases, Ann Rheum Dis, doi:10.1101/2020.05
Pablos, Galindo, Carmona, Retuerto, Lledó et al., Clinical Outcomes of Patients with COVID-19 and Chronic Inflammatory and Autoimmune Rheumatic Diseases: A Multicentric Matched-Cohort Study, doi:10.1101/2020.06.18.20133645
Peñalver, None
Robles, None
Roi, Flores, None
Rosenbaum, Rubin, The central role of the propensity score in observational studies for causal effects, Biometrika
Rosenberg, Dufort, Udo, Wilberschied, Kumar et al., Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State, JAMA, doi:10.1001/jama.2020.8630
Savarino, Boelaert, Cassone, Majori, Cauda, Effects of chloroquine on viral infections: an old drug against today's diseases?, Lancet Infect Dis
Sekhon, Multivariate and propensity score matching software with automated balance optimization: the matching package for R, Journal of Statistical Software, doi:10.18637/jss.v042.i07
Shah, Das, Jain, Misra, Negi, A systematic review of the prophylactic role of chloroquine and hydroxychloroquine in coronavirus disease-19 (COVID-19), Int J Rheum Dis, doi:10.1111/1756-185X.13842
Silva, Boyd, Wallwork, Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot
Tang, Cao, Han, Wang, Chen et al., Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial, BMJ, doi:10.1136/bmj.m1849
Teresa, Guisado, None
Tobal, None
Torio, None
Villa, Mandell, Trastornos cardiovasculares y enfermedad reumatica, Rev Esp Cardiol
Yaox, Zhang, Cui, Huang, Niu, In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome main point: hydroxychloroquine was found to be more potent than chloroquine at inhibiting SARS-CoV-2 in vit, Clin Infect Dis
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult In patients with COVID-19 in Wuhan, China: a retrospective cohort study, Lancet
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit